MAPT and Alzheimer disease: Together with our findings, these data suggest that TYK2 might be downstream of Aβ-induced pathology and upstream of tau pathology, making it a candidate contributor to the toxic effects of Aβ on tau in AD, in addition to AMP-activated protein kinase54–56, GSK3β57 and others58.